16
May

Israeli biotech Kamada watched its shares dive more than 30% on Friday after its treatment for a rare inherited disorder failed to beat out placebo in a pivotal trial.

…read more

Source: Kamada tanks as its lead drug can’t top placebo

    

0 No comments